Results from a phase II trial of a targeted treatment in triple-negative breast cancer suggests the potential for a new therapy for this type of breast cancer.
The trial added the epidermal growth factor receptor antagonist Erbitux to cisplatin, a first generation platinum-based chemotherapy drug, and compared it against receiving cisplatin alone. Patients in the Erbitux plus cisplatin arm saw their tumour response rate double, along with their progression-free survival time.
The phase II trial merely lays the groundwork for a phase III trial involving a substantially larger patient population.
Erbitux is FDA-approved for the treatment of some squamous cell carcinomas of the head and neck, either as a single agent or in combination with radiotherapy. It is also approved as a single agent or in combination with irinotecan for the treatment of some colorectal cancers.
CANCER TYPE(S)
Triple negative breast cancer
TREATMENT TYPE(S)
Biological treatment
Source
Reuters
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
